Ad is loading...
CRSP
Price
$47.88
Change
+$1.59 (+3.43%)
Updated
Nov 22 closing price
87 days until earnings call
OMER
Price
$10.91
Change
+$3.18 (+41.14%)
Updated
Nov 22 closing price
95 days until earnings call
Ad is loading...

CRSP vs OMER

Header iconCRSP vs OMER Comparison
Open Charts CRSP vs OMERBanner chart's image
CRISPR Therapeutics AG
Price$47.88
Change+$1.59 (+3.43%)
Volume$1.5M
CapitalizationN/A
Omeros
Price$10.91
Change+$3.18 (+41.14%)
Volume$4.07M
CapitalizationN/A
CRSP vs OMER Comparison Chart
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
OMER
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
CRSP vs. OMER commentary
Nov 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Sell and OMER is a Hold.

COMPARISON
Comparison
Nov 23, 2024
Stock price -- (CRSP: $47.88 vs. OMER: $10.91)
Brand notoriety: CRSP and OMER are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 106% vs. OMER: 567%
Market capitalization -- CRSP: $4.09B vs. OMER: $632.23M
CRSP [@Biotechnology] is valued at $4.09B. OMER’s [@Biotechnology] market capitalization is $632.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $450.11B to $0. The average market capitalization across the [@Biotechnology] industry is $2.6B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileOMER’s FA Score has 1 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • OMER’s FA Score: 1 green, 4 red.
According to our system of comparison, OMER is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 4 TA indicator(s) are bullish while OMER’s TA Score has 5 bullish TA indicator(s).

  • CRSP’s TA Score: 4 bullish, 6 bearish.
  • OMER’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, OMER is a better buy in the short-term than CRSP.

Price Growth

CRSP (@Biotechnology) experienced а +1.33% price change this week, while OMER (@Biotechnology) price change was +61.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.38%. For the same industry, the average monthly price growth was -4.87%, and the average quarterly price growth was +4.35%.

Reported Earning Dates

CRSP is expected to report earnings on Feb 18, 2025.

OMER is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (+2.38% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($4.09B) has a higher market cap than OMER($632M). OMER YTD gains are higher at: 233.639 vs. CRSP (-23.514). OMER has higher annual earnings (EBITDA): -155.96M vs. CRSP (-313.08M). CRSP has more cash in the bank: 1.94B vs. OMER (123M). OMER has less debt than CRSP: OMER (209M) vs CRSP (228M). CRSP has higher revenues than OMER: CRSP (200M) vs OMER (0).
CRSPOMERCRSP / OMER
Capitalization4.09B632M647%
EBITDA-313.08M-155.96M201%
Gain YTD-23.514233.639-10%
P/E RatioN/AN/A-
Revenue200M0-
Total Cash1.94B123M1,574%
Total Debt228M209M109%
FUNDAMENTALS RATINGS
CRSP vs OMER: Fundamental Ratings
CRSP
OMER
OUTLOOK RATING
1..100
6893
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
45
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9311
PRICE GROWTH RATING
1..100
7634
P/E GROWTH RATING
1..100
86100
SEASONALITY SCORE
1..100
5095

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

OMER's Valuation (45) in the Biotechnology industry is in the same range as CRSP (63). This means that OMER’s stock grew similarly to CRSP’s over the last 12 months.

OMER's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRSP (100). This means that OMER’s stock grew similarly to CRSP’s over the last 12 months.

OMER's SMR Rating (11) in the Biotechnology industry is significantly better than the same rating for CRSP (93). This means that OMER’s stock grew significantly faster than CRSP’s over the last 12 months.

OMER's Price Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for CRSP (76). This means that OMER’s stock grew somewhat faster than CRSP’s over the last 12 months.

CRSP's P/E Growth Rating (86) in the Biotechnology industry is in the same range as OMER (100). This means that CRSP’s stock grew similarly to OMER’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPOMER
RSI
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
88%
Momentum
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 1 day ago
77%
MACD
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
75%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 1 day ago
82%
Advances
ODDS (%)
Bullish Trend 6 days ago
81%
Bullish Trend 1 day ago
81%
Declines
ODDS (%)
Bearish Trend 10 days ago
85%
Bearish Trend 6 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
78%
Aroon
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
83%
View a ticker or compare two or three
Ad is loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
OMER
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DTSVX29.750.52
+1.78%
Wilshire Small Company Value Invmt
MEMBX30.960.09
+0.29%
MFS Emerging Markets Equity B
AGLCX8.050.01
+0.12%
American Century Focused Global Gr C
MPGSX12.75N/A
N/A
MassMutual Disciplined Gr R5
SMVZX13.62N/A
N/A
Virtus Ceredex Mid-Cap Value Equity R6

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with BEAM. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+3.43%
BEAM - CRSP
74%
Closely correlated
+6.23%
EDIT - CRSP
62%
Loosely correlated
+2.95%
NTLA - CRSP
61%
Loosely correlated
+3.62%
PRME - CRSP
60%
Loosely correlated
+7.74%
RXRX - CRSP
57%
Loosely correlated
-0.87%
More

OMER and

Correlation & Price change

A.I.dvisor indicates that over the last year, OMER has been loosely correlated with CRSP. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if OMER jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OMER
1D Price
Change %
OMER100%
+41.14%
CRSP - OMER
43%
Loosely correlated
+3.43%
VCYT - OMER
40%
Loosely correlated
+1.67%
BEAM - OMER
39%
Loosely correlated
+6.23%
FATE - OMER
38%
Loosely correlated
+10.63%
VRDN - OMER
38%
Loosely correlated
+2.96%
More